Cure My Disease

Don't miss your cure!

 Log in / Sign up

Biopsies may reveal why some cancers respond to immunotherapy

NCT ID NCT03412058

Terminated Knowledge-focused Sponsor: UNICANCER Source: ClinicalTrials.gov ↗

First seen Aug 03, 2026 · Last updated Aug 04, 2026 · Updated 1 time

Summary

This study is looking at whether tumor biopsies can help predict which patients with melanoma, non-small cell lung cancer, or head and neck cancer will respond to immunotherapy drugs called PD-1 or PD-L1 inhibitors. Researchers will collect tissue samples from about 152 adults before, during, and after treatment to look for patterns that match with tumor shrinkage. The goal is to develop a 'response signature' that could guide treatment decisions in the future.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Tumor biopsies (tissue samples) taken before, during, and after treatment with PD-1 or PD-L1 inhibitors (immunotherapy drugs)
What this could lead to
If successful, this could help doctors identify which patients are most likely to benefit from immunotherapy, avoiding unnecessary treatments and side effects.
What could go wrong
The study is observational and does not test a new treatment. The predictive signature may not prove accurate, and results may not apply to all patients or cancer types.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

head and neck squamous cell carcinoma melanoma non-small cell lung carcinoma Squamous Cell Carcinoma of Head and Neck

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEAD AND NECK SQUAMOUS CELL CARCINOMA MELANOMA NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

  • CHU Saint-Etienne, Hôpital Nord

    Saint-Etienne, France

  • CHU de Tours

    Tours, France

  • Centre Antoine Lacassagne

    Nice, France

  • Centre Eugène Marquis

    Rennes, France

  • Centre Georges François Leclerc

    Dijon, France

  • Centre Hospitalier Inter. de Creteil

    Créteil, France

  • Centre Hospitalier de Caen

    Caen, France

  • Centre Jean Perrin

    Clermont-Ferrand, 63011, France

  • Centre Léon Bérard

    Lyon, France

  • Centre Oscar lambret

    Lille, France

  • Gustave Roussy

    Villejuif, France

  • Institut Bergonie

    Bordeaux, France

  • Institut Cancérologie de Lorraine

    Vandœuvre-lès-Nancy, France

  • Institut Claudius Regaud - IUCT- 0

    Toulouse, France

  • Institut Curie

    Paris, France

  • Institut Curie - Hôpital René Huguenin

    Saint-Cloud, France

  • Institut Jean Godinot

    Reims, France

  • Institut Régional du Cancer de Montpellier

    Montpellier, France

  • Institut de cancérologie de l'ouest

    Nantes, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.